Navigating Access Barriers and Treatment Gaps in HFpEF Care

Access to care remains a major determinant of heart failure with preserved ejection fraction (HFpEF) outcomes. Panelists noted that disparities in insurance coverage, drug costs, and specialist availability limit the adoption of newer therapies such as finerenone.

They discussed how expanding formulary access, streamlining prior authorization processes, and improving clinician education can help close these gaps. Collaborative models between cardiology, primary care, and pharmacy teams were highlighted as effective tools for improving access.

Ultimately, addressing systemic barriers is essential for translating clinical advances into real-world benefit. The panel agreed that equity in care delivery must remain a central goal as HFpEF management continues to evolve.